{
  "eval_id": "S21",
  "timestamp": "2025-09-19T09:02:53.395855+00:00",
  "model": "gpt-4o",
  "temperature": 0.6,
  "rep_input": "Clinically, what are the on-label points I should know about Trodelvy in HR+/HER2- after prior CDK4/6?",
  "model_output": "Trodelvy is indicated for HR+/HER2- metastatic breast cancer after prior endocrine therapy and at least two systemic treatments, including a CDK4/6 inhibitor. It’s important to assess the patient’s overall health, prior lines of therapy, and specific treatment goals. Please email me the SmPC or EPAR for any specific figures or further detailed questions."
}